An update on computational oral absorption simulation

Bibliography

• Teorell T. Kinetics of distribution of substances administered to the body. Arch Int Pharmacodyn Ther 1937;57:205-40
   Google Scholar
• Kramer J, Grady LT, Gajendran J. Pharmaceutical dissolution testing. USA: 2005
   Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics. New York: 1975
   Google Scholar
• Dressman JB, Amidon GL, Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci 1985;74:588-9
   PubMed Web of Science ®Google Scholar
• Dressman JB, Fleisher D. Mixing-tank model for predicting dissolution rate control of oral absorption. J Pharm Sci 1986;75:109-16
   PubMed Web of Science ®Google Scholar
• Chen H-SG, Gross JF. Physiologically-based pharmacokinetic models for anticancer drugs. Cancer Chemother Pharmacol 1979;2:85-94
   PubMed Web of Science ®Google Scholar
• Himmelstein KJ, Bischoff KB. Models of ARA-C chemotherapy of L1210 leukemia in mice. J Pharmacokinet Biopharm 1973;1:69-81
   Google Scholar
• Himmelstein KJ, Bischoff KB. Mathematical representations of cancer chemotherapy effects. J Pharmacokinet Biopharm 1973;1:51-68
   Google Scholar
• Himmelstein KJ, Lutz RJ. A review of the applications of physiologically-based pharmacokinetic modeling. J Pharmacokinet Biopharm 1979;7:127-45
   PubMedGoogle Scholar
• Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci 1964;53:1392-403
   PubMed Web of Science ®Google Scholar
• Loo JCK, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci 1968;57:918-28
   PubMed Web of Science ®Google Scholar
• Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton, IL: 1975
   Google Scholar
• Dressman JB, Berardi RR, Elta TM, Absorption of flurbiprofen in the fed and fasted states. Pharm Res 1992;9:901-7
   PubMed Web of Science ®Google Scholar
• Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. Stockholm, Sweden: 2001
   Google Scholar
• Levy G. Effect of dosage form on drug absorption a frequent variable in clinical pharmacology. Arch Int Pharmacodyn Ther 1964;152:59-68
   PubMedGoogle Scholar
• United States Pharmacopeial Convention. The United States Pharmacopeia (USP); 2010
   Google Scholar
• Mauger DT, Chinchilli VM. In vitro-in vivo relationships for oral extended-release products. J Biopharm Stat 1997;7:565-78
   PubMedGoogle Scholar
• Jantratid E, Janssen N, Chokshi K, Designing biorelevant dissolution tests for lipid formulations. Case example – Lipid suspension of RZ-50. Eur J Pharm Biopharm 2008;69:776-85
   PubMed Web of Science ®Google Scholar
• Jantratid E, DeMaio V, Ronda E, Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified -release pellet dosage form. J Pharm Sci 2009;37:434-41
   Web of Science ®Google Scholar
• Haggard HW. The absorption, distribution and elimination of ethyl ether. J Biol Chem 1924;59:737-802
   Google Scholar
• Kawai R, Lemaire M, Steimer JL, Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 1994;22:327-65
   PubMedGoogle Scholar
• Teorell T. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch Int Pharmacodyn Ther 1937;57:202-5
   Google Scholar
• Theil FP, Guentert TW, Haddad S, Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 2003;138:29-49
   PubMed Web of Science ®Google Scholar
• Dressman JB, Thelen K, Jantratid E. Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet 2008;47:655-67
   PubMed Web of Science ®Google Scholar
• DeBuck SS, Mackie CE. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin Drug Metab Toxicol 2007;3:865-78
   PubMed Web of Science ®Google Scholar
• Edginton AN, Theil FP, Schmitt W, Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008;4:1143-52
   PubMed Web of Science ®Google Scholar
• Nestorov I. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2007;3:235-49
   PubMed Web of Science ®Google Scholar
• Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51:45-73
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhang L, Grillo JA, Applications of Physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011;89:259-67
   PubMed Web of Science ®Google Scholar
• Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001;50(Suppl 1):S41-67
   PubMed Web of Science ®Google Scholar
• Jamei M, Turner D, Yang J, Population-based mechanistic prediction of oral drug absorption. AAPS J 2009;11:225-37
   PubMed Web of Science ®Google Scholar
• Levitt DG. PKQuest: measurement of intestinal absorption and first pass metabolism - application to human ethanol pharmacokinetics. BMC Clin Pharmacol 2002;2:4
   PubMedGoogle Scholar
• Levitt DG. PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol. BMC Clin Pharmacol 2002;2:5
   PubMedGoogle Scholar
• Thelen K, Coboeken K, Willmann S, Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans – Part I: oral solutions. J Pharm Sci 2011; accepted
   Web of Science ®Google Scholar
• Thomas S, Brightman F, Gill H, Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. J Pharm Sci 2008;97:4557-74
   PubMed Web of Science ®Google Scholar
• Tvrdonova M, Dedik L, Mircioiu C, Physiologically motivated time-delay model to account for mechanisms underlying enterohepatic circulation of piroxicam in human beings. Basic Clin Pharmacol Toxicol 2009;104:35-42
   PubMed Web of Science ®Google Scholar
• Willmann S, Schmitt W, Keldenich J, A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res 2003;20:1766-71
   PubMed Web of Science ®Google Scholar
• Willmann S, Schmitt W, Keldenich J, A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004;47:4022-31
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999;186:119-25
   PubMed Web of Science ®Google Scholar
• Yu LX, Lipka E, Crison JR, Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev 1996;19:359-76
   PubMed Web of Science ®Google Scholar
• Sawamoto T, Haruta S, Kurosaki Y, Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability. J Pharm Pharmacol 1997;49:450-7
   PubMed Web of Science ®Google Scholar
• Kimura T, Higaki K. Gastrointestinal transit and drug absorption. Biol Pharm Bull 2002;25:149-64
   PubMed Web of Science ®Google Scholar
• Grass GM. Simulation models to predict oral drug absorption from in vitro data. Adv Drug Deliv Rev 1997;23:199-219
   Web of Science ®Google Scholar
• Cloe Predict HIA. cyprotex, 2011. Available from: www.cyprotex.com [Last accessed 25 April 2011]
   Google Scholar
• Jamei M, Yang J, Turner D, A novel physiologically-based mechanistic model for predicting oral drug absorption: the advanced dissolution, absorption, and metabolism (ADAM) model. PKUK; Edinburgh, UK: 2007
   Google Scholar
• Thelen K, Coboeken K, Willmann S, Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans – Part II: Extension to describe performance of solid dosage forms. J Pharm Sci 2011; submitted
   Web of Science ®Google Scholar
• Norris DA, Leesman GD, Sinko PJ, Development of predictive pharmacokinetic simulation models for drug discovery. J Control Release 2000;65:55-62
   PubMed Web of Science ®Google Scholar
• Parrott N, Lave T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur J Pharm Sci 2002;17:51-61
   PubMed Web of Science ®Google Scholar
• Anderton MJ, Manson MM, Verschoyle R, Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos 2004;32:632-8
   PubMed Web of Science ®Google Scholar
• Gao G, Law FC. Physiologically based pharmacokinetics of matrine in the rat after oral administration of pure chemical and ACAPHA. Drug Metab Dispos 2009;37:884-91
   PubMed Web of Science ®Google Scholar
• Mudra DR, Jin JY, Borchardt RT. Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism. J Pharm Sci 2010;99:999-1015
   PubMed Web of Science ®Google Scholar
• Parrott N, Lukacova V, Fraczkiewicz G, Predicting pharmacokinetics of drugs using physiologically based modeling–application to food effects. AAPS J 2009;11:45-53
   PubMed Web of Science ®Google Scholar
• Takano R, Takata N, Saito R, Quantitative analysis of the effect of supersaturation on in vivo drug absorption. Mol Pharm 2010. [Epub ahead of print]
   PubMedGoogle Scholar
• Tam D, Tirona RG, Pang KS. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 2003;31:373-83
   PubMed Web of Science ®Google Scholar
• Thongnopnua P, Massarella JW, Zimmerman CL. The pharmacokinetics of etretinate and its metabolites in the dog. Drug Metab Dispos 1989;17:473-80
   PubMed Web of Science ®Google Scholar
• Wong H, Theil FP, Cui Y, Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling. Drug Metab Dispos 2010;38:1029-38
   PubMed Web of Science ®Google Scholar
• Zhang F, Tagen M, Throm S, Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos 2011;39:15-21
   PubMed Web of Science ®Google Scholar
• DeBuck SS, Sinha VK, Fenu LA, The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 2007;35:649-59
   PubMed Web of Science ®Google Scholar
• STELLA - Systems thinking for education and research. isee systems, Inc., Cognitus Limited, 2011. Available from: http://www.iseesystems.com/softwares/Education/StellaSoftware.aspx [Last accessed 16 February 2011]
   Google Scholar
• Takano R, Furumoto K, Shiraki K, Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm Res 2008;25:2334-44
   PubMed Web of Science ®Google Scholar
• GastroPlus. simulationsplus, Inc., 2010. Available from: http://www.simulations-plus.com/Products [Last accessed 16 February 2011]
   Google Scholar
• SimCYP software. Simcyp Ltd., 2011. Available from: http://www.simcyp.com/ [Last accessed 16 February 2011]
   Google Scholar
• PK-Sim software. Bayer Technology Services GmbH, 2011. Available from: http://www.systems-biology.com/products/pk-sim.html [Last accessed 16 February 2011]
   Google Scholar
• Thelen K, Dressman JB, Sevestre M, The minipig in PBPK modeling. 2nd edition. Pharmaceutical Sciences Fair & Exhibition; Nice, France: 2009
   Google Scholar
• Willmann S, Edginton AN, Dressman JB. Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharm Res 2007;24:1275-82
   PubMed Web of Science ®Google Scholar
• Willmann S, Thelen K, Becker C, Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. Eur J Pharm Biopharm 2010;76:83-94
   PubMed Web of Science ®Google Scholar
• Peters SA, Hultin L. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn 2008;35:1-30
   PubMed Web of Science ®Google Scholar
• Peters SA. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin Pharmacokinet 2008;47:245-59
   PubMed Web of Science ®Google Scholar
• Brandl M, Wu X, Holper M, Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability. Drug Dev Ind Pharm 2008;34:683-91
   PubMed Web of Science ®Google Scholar
• Parrott N, Paquereau N, Coassolo P, An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 2005;94:2327-43
   PubMed Web of Science ®Google Scholar
• Galia E, Nicolaides E, Horter D, Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998;15:698-705
   PubMed Web of Science ®Google Scholar
• Nicolaides E, Symillides M, Dressman JB, Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res 2001;18:380-8
   PubMed Web of Science ®Google Scholar
• Dannenfelser RM, He H, Joshi Y, Development of clinical dosage forms for a poorly water soluble drug I: application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 2004;93:1165-75
   PubMed Web of Science ®Google Scholar
• Kuentz M, Nick S, Parrott N, A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 2006;27:91-9
   PubMed Web of Science ®Google Scholar
• Dressman JB. Comparison of canine and human gastrointestinal physiology. Pharm Res 1986;3:123-31
   PubMed Web of Science ®Google Scholar
• Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995;16:351-80
   PubMed Web of Science ®Google Scholar
• Jinno J, Kamada N, Miyake M, Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 2006;111:56-64
   PubMed Web of Science ®Google Scholar
• Yuan LG, Luo XY, Zhu LX, A physiologically based pharmacokinetic model for valnemulin in rats and extrapolation to pigs. J Vet Pharmacol Ther 2011;34:224-31
   PubMed Web of Science ®Google Scholar
• Allan G, Davis J, Dickins M, Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. Xenobiotica 2008;38:620-40
   PubMed Web of Science ®Google Scholar
• Brochot A, Zamacona M, Stockis A. Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy. Basic Clin Pharmacol Toxicol 2010;106:256-62
   PubMed Web of Science ®Google Scholar
• DeBuck SS, Sinha VK, Fenu LA, Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007;35:1766-80
   PubMed Web of Science ®Google Scholar
• Heimbach T, Lakshminarayana SB, Hu W, Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data. AAPS J 2009;11:602-14
   PubMed Web of Science ®Google Scholar
• Hosseini-Yeganeh M, McLachlan AJ. Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrob Agents Chemother 2002;46:2219-28
   PubMed Web of Science ®Google Scholar
• Ploeger B, Mensinga T, Sips A, A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling. Pharm Res 2000;17:1516-25
   PubMed Web of Science ®Google Scholar
• Jones HM, Parrott N, Jorga K, A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006;45:511-42
   PubMed Web of Science ®Google Scholar
• Parrott N, Jones H, Paquereau N, Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin Pharmacol Toxicol 2005;96:193-9
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 2000;89:16-35
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 2002;91:129-56
   PubMed Web of Science ®Google Scholar
• Poulin P, Theil FP. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 2009;98:4941-61
   PubMed Web of Science ®Google Scholar
• Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005;94:1259-76
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006;95:1238-57
   PubMed Web of Science ®Google Scholar
• Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 2007;24:918-33
   PubMed Web of Science ®Google Scholar
• Badhan R, Penny J, Galetin A, Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J Pharm Sci 2009;98:2180-97
   PubMed Web of Science ®Google Scholar
• Badwan A, Remawi M, Qinna N, Enhancement of oral bioavailability of insulin in humans. Neurol Endocrinol Lett 2009;30:74-8
   PubMed Web of Science ®Google Scholar
• Bolger MB, Lukacova V, Woltosz WS. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J 2009;11:353-63
   PubMed Web of Science ®Google Scholar
• Bruyere A, Decleves X, Bouzom F, Effect of Variations in the Amounts of P-Glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the Human Small Intestine on PBPK Models for Predicting Intestinal First Pass. Mol Pharm 2010. [Epub ahead of print]
   PubMedGoogle Scholar
• Cai H, Stoner C, Reddy A, Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability. Int J Pharm 2006;308:133-9
   PubMedGoogle Scholar
• Darwich AS, Neuhoff S, Jamei M, Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “advanced dissolution, absorption, metabolism (ADAM)” model. Curr Drug Metab 2010;11:716-29
   PubMed Web of Science ®Google Scholar
• Gibson CR, Bergman A, Lu P, Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling. Xenobiotica 2009;39:637-48
   PubMed Web of Science ®Google Scholar
• Grbic S, Parojcic J, Ibric S, In vitro-in vivo correlation for gliclazide immediate-release tablets based on mechanistic absorption simulation. AAPS PharmSciTech 2011;12:165-71
   PubMed Web of Science ®Google Scholar
• Jones HM, Parrott N, Ohlenbusch G, Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin Pharmacokinet 2006;45:1213-26
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Wu Y, Chin A. Prediction of micronized aprepitant food effect through absorption modeling. AAPS Annual Meeting and Exposition 2007; 2007
   Google Scholar
• Kortejarvi H, Urtti A, Yliperttula M. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharm Sci 2007;30:155-66
   PubMed Web of Science ®Google Scholar
• Kovacevic I, Parojcic J, Homsek I, Justification of Biowaiver for Carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm 2009;6:40-7
   PubMed Web of Science ®Google Scholar
• Kovacevic I, Parojcic J, Tubic-Grozdanis M, An investigation into the importance of “very rapid dissolution” criteria for drug bioequivalence demonstration using gastrointestinal simulation technology. AAPS J 2009;11:381-4
   PubMed Web of Science ®Google Scholar
• Kuentz M. Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J 2008;10:473-9
   PubMed Web of Science ®Google Scholar
• Lindahl A, Sjoberg A, Bredberg U, Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. Mol Pharm 2004;1:347-56
   PubMed Web of Science ®Google Scholar
• Lukacova V, Woltosz WS, Bolger MB. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data. AAPS J 2009;11:323-34
   PubMed Web of Science ®Google Scholar
• Okumu A, DiMaso M, Lobenberg R. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm Res 2008;25:2778-85
   PubMed Web of Science ®Google Scholar
• Okumu A, DiMaso M, Lobenberg R. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. Eur J Pharm Biopharm 2009;72:91-8
   PubMed Web of Science ®Google Scholar
• Perdaems N, Blasco H, Vinson C, Predictions of metabolic drug-drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 2010;49:239-58
   PubMed Web of Science ®Google Scholar
• Shono Y, Jantratid E, Janssen N, Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm 2009;73:107-14
   PubMed Web of Science ®Google Scholar
• Shono Y, Jantratid E, Kesisoglou F, Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm 2010;76:95-104
   PubMed Web of Science ®Google Scholar
• Sperry DC, Thomas SJ, Lobo E. Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug. Mol Pharm 2010. [Epub ahead of print]
   Google Scholar
• Thelen K, Jantratid E, Dressman JB, Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing. J Pharm Sci 2010;99:2899-904
   PubMed Web of Science ®Google Scholar
• Tsume Y, Amidon GL. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol Pharm 2010;7:1235-43
   PubMed Web of Science ®Google Scholar
• Tubic-Grozdanis M, Bolger MB, Langguth P. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J 2008;10:213-26
   PubMed Web of Science ®Google Scholar
• Wei H, Dalton C, Di MM, Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. Eur J Pharm Biopharm 2008;69:1046-56
   PubMed Web of Science ®Google Scholar
• Willmann S, Edginton AN, Kleine-Besten M, Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. J Pharm Pharmacol 2009;61:891-9
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007;8:676-84
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm 1998;45:199-203
   PubMed Web of Science ®Google Scholar
• Cong D, Doherty M, Pang KS. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab Dispos 2000;28:224-35
   PubMed Web of Science ®Google Scholar
• Tubic M, Wagner D, Spahn-Langguth H, In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res 2006;23:1712-20
   PubMed Web of Science ®Google Scholar
• The European Agency for the Evaluation of Medicinal Products (EMEA) - Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the Investigation of Bioavailability and Bioequivalence; 2002
   Google Scholar
• U.S. Department of Health and Human Services (Food and Drug Administration) - Center for Drug Evaluation and Research (CDER). Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; 2000
   Google Scholar
• European Medicines Agency (EMA). Guideline on the investigation of bioequivalence; 2010
   Google Scholar
• Edginton AN, Willmann S. Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 2008;47:743-52
   PubMed Web of Science ®Google Scholar
• Thompson CM, Johns DO, Sonawane B, Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. J Toxicol Environ Health B Crit Rev 2009;12:1-24
   PubMed Web of Science ®Google Scholar
• Willmann S, Schmitt W, Stass H, Physiologically-based pharmacokinetic simulations of ciprofloxacin in obese and renally impaired individuals. EUFEPS poster presentation; 2006
   Google Scholar
• Becker C, Coboeken K, Kuepfer L, WB-PBPK Population modeling to simulate the influence of weight and age on the PK of a combined oral contraceptive containing drospirenone and ethinylestradiol. PAGE 2008; Marseille
   Google Scholar
• Becker C, Willmann S, Eissing T, Whole-body physiologically-based pharmacokinetic modeling of moxifloxacin to support a translational approach in pediatric study design. PAGE 2009; St. Petersburg
   Google Scholar
• Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 2006;45:1013-34
   PubMed Web of Science ®Google Scholar
• Willmann S, Edginton AN, Coboeken K, Risk to the breast-fed neonate from codeine treatment to the mother: a Quantitative Mechanistic Modeling Study. Clin Pharmacol Ther 2009;86:634-43
   PubMed Web of Science ®Google Scholar
• Andersen ME. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicol Lett 1995;79:35-44
   PubMed Web of Science ®Google Scholar
• Bois FY, Jamei M, Clewell HJ. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 2010;278:256-67
   PubMed Web of Science ®Google Scholar
• Clewell HJ III, Andersen ME, Wills RJ, A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol 1997;36:S77-85
   PubMed Web of Science ®Google Scholar
• Edginton AN, Ritter L. Predicting plasma concentrations of bisphenol A in children younger than 2 years of age after typical feeding schedules, using a physiologically based toxicokinetic model. Environ Health Perspect 2009;117:645-52
   PubMed Web of Science ®Google Scholar
• Godin SJ, DeVito MJ, Hughes MF, Physiologically based pharmacokinetic modeling of deltamethrin: development of a rat and human diffusion-limited model. Toxicol Sci 2010;115:330-43
   PubMed Web of Science ®Google Scholar
• Haddad S, Tardif GC, Tardif R. Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes. J Toxicol Environ Health A 2006;69:2095-136
   PubMed Web of Science ®Google Scholar
• Kim AH, Kohn MC, Portier CJ, Impact of physiologically based pharmacokinetic modeling on benchmark dose calculations for TCDD-induced biochemical responses. Regul Toxicol Pharmacol 2002;36:287-96
   PubMed Web of Science ®Google Scholar
• Kirman CR, Sweeney LM, Meek ME, Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. Regul Toxicol Pharmacol 2003;38:345-67
   PubMed Web of Science ®Google Scholar
• Krishnan K, Crouse LC, Bazar MA, Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats. J Appl Toxicol 2009;29:629-37
   PubMed Web of Science ®Google Scholar
• Lilly PD, Andersen ME, Ross TM, A physiologically based pharmacokinetic description of the oral uptake, tissue dosimetry, and rates of metabolism of bromodichloromethane in the male rat. Toxicol Appl Pharmacol 1998;150:205-17
   PubMed Web of Science ®Google Scholar
• Loizou GD, Spendiff M. A human PBPK model for ethanol describing inhibition of gastric motility. J Mol Histol 2004;35:687-96
   PubMed Web of Science ®Google Scholar
• Lu C, Holbrook CM, Andres LM. The implications of using a physiologically based pharmacokinetic (PBPK) model for pesticide risk assessment. Environ Health Perspect 2010;118:125-30
   PubMed Web of Science ®Google Scholar
• McMullin TS, Hanneman WH, Cranmer BK, Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. Toxicology 2007;240:1-14
   Google Scholar
• Metivier H. A new model for the human alimentary tract: the work of a Committee 2 task group. Radiat Prot Dosimetry 2003;105:43-8
   PubMed Web of Science ®Google Scholar
• Mirfazaelian A, Kim KB, Anand SS, Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat. Toxicol Sci 2006;93:432-42
   PubMed Web of Science ®Google Scholar
• Oomen AG, Rompelberg CJ, Bruil MA, Development of an in vitro digestion model for estimating the bioaccessibility of soil contaminants. Arch Environ Contam Toxicol 2003;44:281-7
   PubMed Web of Science ®Google Scholar
• Semino G, Lilly P, Andersen ME. A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride. Toxicology 1997;117:25-33
   PubMed Web of Science ®Google Scholar
• Shin BS, Hong SH, Bulitta JB, Physiologically based pharmacokinetics of zearalenone. J Toxicol Environ Health A 2009;72:1395-405
   PubMed Web of Science ®Google Scholar
• Shin BS, Hwang SW, Bulitta JB, Assessment of bisphenol A exposure in Korean pregnant women by physiologically based pharmacokinetic modeling. J Toxicol Environ Health A 2010;73:1586-98
   PubMed Web of Science ®Google Scholar
• Staats DA, Fisher JW, Connolly RB. Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models. A two-compartment description. Drug Metab Dispos 1991;19:144-8
   PubMed Web of Science ®Google Scholar
• Takano R, Murayama N, Horiuchi K, Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. Regul Toxicol Pharmacol 2010;58:252-8
   PubMed Web of Science ®Google Scholar
• Tornero-Velez R, Mirfazaelian A, Kim KB, Evaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model. Toxicol Appl Pharmacol 2010;244:208-17
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Horiuchi K, Takano R, Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. Int J Environ Res Public Health 2010;7:3406-21
   PubMed Web of Science ®Google Scholar
• Zhang X, Lionberger RA, Davit BM, Utility of physiologically based absorption modeling in implementing Quality by Design in drug development. AAPS J 2011;13:59-71
   PubMed Web of Science ®Google Scholar
• Eissing T, Kuepfer L, Becker C, A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol 2011;2:4
   PubMed Web of Science ®Google Scholar